Aptevo Therapeutics Stock Price, News & Analysis (NASDAQ:APVO)

$3.27 +0.13 (+4.14 %)
(As of 02/23/2018 05:36 AM ET)
Previous Close$3.14
Today's Range$3.17 - $3.33
52-Week Range$1.15 - $4.85
Volume105,400 shs
Average Volume211,053 shs
Market Capitalization$67.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.2

About Aptevo Therapeutics (NASDAQ:APVO)

Aptevo Therapeutics logoAptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APVO
CUSIPN/A
Phone206-838-0500

Debt

Debt-to-Equity Ratio0.19%
Current Ratio7.76%
Quick Ratio7.67%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$36.43 million
Price / Sales1.92
Cash FlowN/A
Price / CashN/A
Book Value$2.50 per share
Price / Book1.31

Profitability

Trailing EPSN/A
Net Income$-112,410,000.00
Net Margins5.40%
Return on Equity-28.03%
Return on Assets-17.46%

Miscellaneous

Employees118
Outstanding Shares21,440,000

Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc (NASDAQ:APVO) posted its earnings results on Thursday, August, 10th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.61) by $0.08. The biotechnology company earned $10.76 million during the quarter. Aptevo Therapeutics had a net margin of 5.40% and a negative return on equity of 28.03%. View Aptevo Therapeutics' Earnings History.

When will Aptevo Therapeutics make its next earnings announcement?

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March, 30th 2018. View Earnings Estimates for Aptevo Therapeutics.

Where is Aptevo Therapeutics' stock going? Where will Aptevo Therapeutics' stock price be in 2018?

1 equities research analysts have issued 1-year price objectives for Aptevo Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Aptevo Therapeutics' share price to reach $6.00 in the next twelve months. View Analyst Ratings for Aptevo Therapeutics.

Who are some of Aptevo Therapeutics' key competitors?

Who owns Aptevo Therapeutics stock?

Aptevo Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sessa Capital IM L.P. (7.59%), Renaissance Technologies LLC (2.00%), BlackRock Inc. (1.64%), Millennium Management LLC (1.00%), Victory Capital Management Inc. (0.91%) and Virtu Financial LLC (0.76%). View Institutional Ownership Trends for Aptevo Therapeutics.

Who sold Aptevo Therapeutics stock? Who is selling Aptevo Therapeutics stock?

Aptevo Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sessa Capital IM L.P., BlackRock Inc., Millennium Management LLC and Spark Investment Management LLC. View Insider Buying and Selling for Aptevo Therapeutics.

Who bought Aptevo Therapeutics stock? Who is buying Aptevo Therapeutics stock?

Aptevo Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Victory Capital Management Inc., Virtu Financial LLC and Acadian Asset Management LLC. View Insider Buying and Selling for Aptevo Therapeutics.

How do I buy Aptevo Therapeutics stock?

Shares of Aptevo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of Aptevo Therapeutics stock can currently be purchased for approximately $3.27.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $67.33 million and generates $36.43 million in revenue each year. Aptevo Therapeutics employs 118 workers across the globe.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVE. SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]


MarketBeat Community Rating for Aptevo Therapeutics (APVO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aptevo Therapeutics (NASDAQ:APVO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$6.00$5.00
Price Target Upside: 158.62% upside158.62% upside158.62% upsideN/A

Aptevo Therapeutics (NASDAQ:APVO) Consensus Price Target History

Price Target History for Aptevo Therapeutics (NASDAQ:APVO)

Aptevo Therapeutics (NASDAQ:APVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$6.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Aptevo Therapeutics (NASDAQ:APVO) Earnings History and Estimates Chart

Earnings by Quarter for Aptevo Therapeutics (NASDAQ:APVO)

Aptevo Therapeutics (NASDAQ APVO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/30/2018        
11/9/2017Q3 2017$2.25$0.14$6.17 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.61)($0.53)$10.76 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.71)($0.48)$7.41 millionViewN/AView Earnings Details
3/31/2017Q4 2016$0.01$8.77 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.64)($0.80)$9.41 millionViewN/AView Earnings Details
8/25/2016Q2 2016($0.63)$10.19 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aptevo Therapeutics (NASDAQ:APVO) Earnings Estimates

Current Year EPS Consensus Estimate: $0.43 EPS
Next Year EPS Consensus Estimate: $-2.69 EPS

Dividends

Dividend History for Aptevo Therapeutics (NASDAQ:APVO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aptevo Therapeutics (NASDAQ APVO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.60%
Institutional Ownership Percentage: 34.10%
Insider Trades by Quarter for Aptevo Therapeutics (NASDAQ:APVO)
Institutional Ownership by Quarter for Aptevo Therapeutics (NASDAQ:APVO)

Aptevo Therapeutics (NASDAQ APVO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017Randy Joe MadduxVPBuy25,000$2.76$69,000.0025,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aptevo Therapeutics (NASDAQ APVO) News Headlines

Source:
DateHeadline
Bioblast Pharma (ORPN) versus Aptevo Therapeutics (APVO) Financial ReviewBioblast Pharma (ORPN) versus Aptevo Therapeutics (APVO) Financial Review
www.americanbankingnews.com - February 18 at 1:44 PM
Analysts Expect Aptevo Therapeutics Inc (APVO) to Announce ($0.32) Earnings Per ShareAnalysts Expect Aptevo Therapeutics Inc (APVO) to Announce ($0.32) Earnings Per Share
www.americanbankingnews.com - February 15 at 3:12 PM
Aptevo Therapeutics Inc (APVO) Expected to Post Earnings of -$0.32 Per ShareAptevo Therapeutics Inc (APVO) Expected to Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - February 15 at 1:34 PM
Zacks: Aptevo Therapeutics Inc (APVO) Receives Average Rating of "Strong Buy" from BrokeragesZacks: Aptevo Therapeutics Inc (APVO) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 10 at 3:28 PM
-$0.32 Earnings Per Share Expected for Aptevo Therapeutics Inc (APVO) This Quarter-$0.32 Earnings Per Share Expected for Aptevo Therapeutics Inc (APVO) This Quarter
www.americanbankingnews.com - January 29 at 11:20 AM
Zacks: Analysts Set $6.00 Price Target for Aptevo Therapeutics Inc (APVO)Zacks: Analysts Set $6.00 Price Target for Aptevo Therapeutics Inc (APVO)
www.americanbankingnews.com - January 26 at 10:52 AM
 Aptevo Therapeutics Inc (APVO) Receives Average Recommendation of "Strong Buy" from Analysts Aptevo Therapeutics Inc (APVO) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - January 20 at 9:14 PM
Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - January 17 at 10:36 AM
Zacks: Analysts Anticipate Aptevo Therapeutics Inc (APVO) Will Announce Earnings of -$0.32 Per ShareZacks: Analysts Anticipate Aptevo Therapeutics Inc (APVO) Will Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - January 12 at 1:06 PM
Aptevo Therapeutics (APVO) Commences Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell LymphomaAptevo Therapeutics (APVO) Commences Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma
www.streetinsider.com - January 9 at 4:18 PM
Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell LymphomaAptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma
finance.yahoo.com - January 8 at 10:51 AM
 Aptevo Therapeutics Inc (APVO) Given $6.00 Consensus Price Target by Brokerages Aptevo Therapeutics Inc (APVO) Given $6.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - January 5 at 5:50 PM
Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018
finance.yahoo.com - January 3 at 9:54 AM
Analysts Anticipate Aptevo Therapeutics Inc (APVO) to Announce ($0.32) Earnings Per ShareAnalysts Anticipate Aptevo Therapeutics Inc (APVO) to Announce ($0.32) Earnings Per Share
www.americanbankingnews.com - January 2 at 9:42 PM
Aptevo Therapeutics Inc (APVO) Short Interest UpdateAptevo Therapeutics Inc (APVO) Short Interest Update
www.americanbankingnews.com - January 1 at 1:16 AM
Aptevo Therapeutics (APVO) & Kindred Biosciences (KIN) Head to Head ComparisonAptevo Therapeutics (APVO) & Kindred Biosciences (KIN) Head to Head Comparison
www.americanbankingnews.com - December 27 at 7:30 PM
ETFs with exposure to Aptevo Therapeutics, Inc. : December 27, 2017ETFs with exposure to Aptevo Therapeutics, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 4:55 PM
-$0.32 EPS Expected for Aptevo Therapeutics Inc (APVO) This Quarter-$0.32 EPS Expected for Aptevo Therapeutics Inc (APVO) This Quarter
www.americanbankingnews.com - December 26 at 9:16 PM
Does Aptevo Therapeutics Inc’s (NASDAQ:APVO) 74.9% EPS Growth Reflect The Long-Term Trend?Does Aptevo Therapeutics Inc’s (NASDAQ:APVO) 74.9% EPS Growth Reflect The Long-Term Trend?
finance.yahoo.com - December 19 at 10:45 AM
Analysts Anticipate Aptevo Therapeutics Inc (APVO) to Announce ($0.32) EPSAnalysts Anticipate Aptevo Therapeutics Inc (APVO) to Announce ($0.32) EPS
www.americanbankingnews.com - December 15 at 5:52 AM
ETFs with exposure to Aptevo Therapeutics, Inc. : December 11, 2017ETFs with exposure to Aptevo Therapeutics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 4:23 PM
Aptevo Therapeutics’ Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML SamplesAptevo Therapeutics’ Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples
finance.yahoo.com - December 11 at 11:22 AM
Aptevo Therapeutics Inc. (APVO) VP Randy Joe Maddux Acquires 25,000 SharesAptevo Therapeutics Inc. (APVO) VP Randy Joe Maddux Acquires 25,000 Shares
www.americanbankingnews.com - December 8 at 11:16 PM
 Aptevo Therapeutics Inc. (APVO) Given Consensus Rating of "Strong Buy" by Brokerages Aptevo Therapeutics Inc. (APVO) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 30 at 11:46 PM
Aptevo Therapeutics (APVO) to Conduct Phase 2 Study of Otlertuzumab in PTCLAptevo Therapeutics (APVO) to Conduct Phase 2 Study of Otlertuzumab in PTCL
www.streetinsider.com - November 30 at 4:15 PM
ETFs with exposure to Aptevo Therapeutics, Inc. : November 29, 2017ETFs with exposure to Aptevo Therapeutics, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 4:15 PM
Financial Analysis: Aptevo Therapeutics (APVO) versus Array BioPharma (ARRY)Financial Analysis: Aptevo Therapeutics (APVO) versus Array BioPharma (ARRY)
www.americanbankingnews.com - November 28 at 9:08 PM
Is Aptevo Therapeutics Inc’s (APVO) Balance Sheet Strong Enough To Weather A Storm?Is Aptevo Therapeutics Inc’s (APVO) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 21 at 9:35 PM
Brokerages Anticipate Aptevo Therapeutics Inc. (APVO) to Announce ($0.66) EPSBrokerages Anticipate Aptevo Therapeutics Inc. (APVO) to Announce ($0.66) EPS
www.americanbankingnews.com - November 15 at 11:24 PM
Aptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare ConferenceAptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 14 at 4:25 PM
Short Interest in Aptevo Therapeutics Inc. (APVO) Rises By 31.1%Short Interest in Aptevo Therapeutics Inc. (APVO) Rises By 31.1%
www.americanbankingnews.com - November 13 at 2:32 AM
Aptevo Therapeutics Inc. (APVO) Lowered to "Sell" at ValuEngineAptevo Therapeutics Inc. (APVO) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - November 11 at 7:38 PM
Zacks: Analysts Set $6.00 Price Target for Aptevo Therapeutics Inc. (APVO)Zacks: Analysts Set $6.00 Price Target for Aptevo Therapeutics Inc. (APVO)
www.americanbankingnews.com - November 9 at 5:30 PM
Aptevo Therapeutics Reports Third Quarter 2017 Financial ResultsAptevo Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 5:05 PM
ETFs with exposure to Aptevo Therapeutics, Inc. : November 1, 2017ETFs with exposure to Aptevo Therapeutics, Inc. : November 1, 2017
finance.yahoo.com - November 1 at 4:31 PM
ETFs with exposure to Aptevo Therapeutics, Inc. : November 1, 2017ETFs with exposure to Aptevo Therapeutics, Inc. : November 1, 2017
finance.yahoo.com - November 1 at 4:31 PM
$2.25 EPS Expected for Aptevo Therapeutics Inc. (APVO) This Quarter$2.25 EPS Expected for Aptevo Therapeutics Inc. (APVO) This Quarter
www.americanbankingnews.com - October 31 at 11:08 PM
MBIO Keeps Galloping, GERN On Fast Track, APVO Awes, INSY Continues DescentMBIO Keeps Galloping, GERN On Fast Track, APVO Awes, INSY Continues Descent
www.rttnews.com - October 31 at 10:19 PM
Aptevo Therapeutics (APVO) Announces New Preclinical Data on APVO436Aptevo Therapeutics (APVO) Announces New Preclinical Data on APVO436
www.streetinsider.com - October 31 at 5:16 PM
Aptevo Therapeutics Presents New Preclinical Data on APVO436 – a Next Generation ADAPTIR™ Bispecific Antibody CandidateAptevo Therapeutics Presents New Preclinical Data on APVO436 – a Next Generation ADAPTIR™ Bispecific Antibody Candidate
finance.yahoo.com - October 30 at 4:57 PM
NEOS Soars On Buyout Bid, INSY Plunges On Founders Arrest, CELG BleedsNEOS Soars On Buyout Bid, INSY Plunges On Founder's Arrest, CELG Bleeds
www.rttnews.com - October 27 at 2:13 AM
Critical Contrast: Aptevo Therapeutics (APVO) versus Its PeersCritical Contrast: Aptevo Therapeutics (APVO) versus Its Peers
www.americanbankingnews.com - October 25 at 8:36 AM
Alligator Bioscience Aptevo Therapeutics: Tumor Antigen 5T4 Associated with Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527Alligator Bioscience Aptevo Therapeutics: Tumor Antigen 5T4 Associated with Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527
www.nasdaq.com - October 24 at 5:42 PM
Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 – a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo TherapeuticsTumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 – a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics
finance.yahoo.com - October 24 at 5:42 PM
Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society MeetingAptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting
finance.yahoo.com - October 16 at 4:48 PM
Aptevo Therapeutics Inc. (APVO) Upgraded at ValuEngineAptevo Therapeutics Inc. (APVO) Upgraded at ValuEngine
www.americanbankingnews.com - October 12 at 11:16 PM
Aptevo Therapeutics: Slowly Grinding HigherAptevo Therapeutics: Slowly Grinding Higher
seekingalpha.com - October 12 at 4:49 PM
Aptevo Therapeutics, Analyst Coverage, ADAPTIR Platform and Recent Drug Asset SaleAptevo Therapeutics, Analyst Coverage, ADAPTIR Platform and Recent Drug Asset Sale
finance.yahoo.com - October 10 at 5:18 PM
ETFs with exposure to Aptevo Therapeutics, Inc. : October 6, 2017ETFs with exposure to Aptevo Therapeutics, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 4:15 PM
Aptevo Therapeutics Inc. (APVO) Given "Overweight" Rating at Piper Jaffray CompaniesAptevo Therapeutics Inc. (APVO) Given "Overweight" Rating at Piper Jaffray Companies
www.americanbankingnews.com - October 5 at 11:20 PM

SEC Filings

Aptevo Therapeutics (NASDAQ:APVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aptevo Therapeutics (NASDAQ:APVO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aptevo Therapeutics (NASDAQ APVO) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.